Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Share-based Compensation for 6 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 2957.08% to $4.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.7 million, a 5172.12% increase, with the full-year FY2024 number at $8.1 million, up 1527.64% from a year prior.
  • Share-based Compensation was $4.5 million for Q3 2025 at Inhibikase Therapeutics, up from $4.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.9 million in Q4 2024 to a low of $30697.0 in Q2 2024.
  • A 5-year average of $1.1 million and a median of $132767.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: crashed 79.15% in 2022, then skyrocketed 13610.6% in 2025.
  • Inhibikase Therapeutics' Share-based Compensation stood at $265850.0 in 2021, then crashed by 62.25% to $100363.0 in 2022, then rose by 21.81% to $122249.0 in 2023, then surged by 6369.14% to $7.9 million in 2024, then tumbled by 42.78% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Share-based Compensation are $4.5 million (Q3 2025), $4.2 million (Q2 2025), and $2.0 million (Q1 2025).